Clinical Trial Update: A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD) [Phase 1, Phase 2]

View source ↗

Summary

The study tested multiple doses of BI 836880 in patients with wet age-related macular degeneration; the Phase 1/2 trial has completed and results were posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• BI 836880

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Wet Macular Degeneration | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-11-20